Department of Breast Surgery, Yokohama Rosai Hospital, Yokohama, Japan.
Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan.
In Vivo. 2021 Jul-Aug;35(4):2439-2444. doi: 10.21873/invivo.12522.
BACKGROUND/AIM: Oncotype DX recurrence score (RS) for breast cancer is a useful tool for determining chemotherapy indication but it is expensive and time-consuming. We determined whether four immuno-histochemical markers, namely human epidermal growth factor 2 (HER2), estrogen receptor (ER), progesterone receptor (PgR), and Ki-67, are predictive of an RS ≥26 in Japanese patients.
The study included 95 Japanese patients evaluated for RS. A predictive model was created using logistic regression analysis.
The discriminant function was calculated as follows: p=1/{1+exp [-(4.611+1.2342×HER2-0.0813×ER- 0.0489 ×PgR+0.0857×Ki67)]}. Using a probability of 0.5 as the cutoff, the accuracy, sensitivity, specificity, positive predictive and negative predictive values were 90.5%, 72.2%, 94.8%, 76.4% and 93.5%, respectively.
The model had a high negative predictive value in predicting RS ≥26 in Japanese patients, indicating that Oncotype DX testing may be omitted in patients with a negative result according to the predictive model.
背景/目的：乳腺癌的 Oncotype DX 复发评分（RS）是确定化疗指征的有用工具，但它既昂贵又耗时。我们旨在确定四种免疫组织化学标志物，即人表皮生长因子 2（HER2）、雌激素受体（ER）、孕激素受体（PgR）和 Ki-67，是否可预测日本患者的 RS≥26。
该研究纳入了 95 名接受 RS 评估的日本患者。使用逻辑回归分析建立预测模型。
判别函数计算如下：p=1/{1+exp [-(4.611+1.2342×HER2-0.0813×ER-0.0489×PgR+0.0857×Ki67)]}。以概率 0.5 作为截断值，该模型的准确性、敏感性、特异性、阳性预测值和阴性预测值分别为 90.5%、72.2%、94.8%、76.4%和 93.5%。
该模型在预测日本患者 RS≥26 方面具有较高的阴性预测值，表明根据预测模型，阴性结果的患者可能无需进行 Oncotype DX 检测。
